A page in the reference notebook
Tesamorelin
Also listed as: Egrifta WR
Keep the record, its references, and your reading question together.
- Product status
- Approved product
- Evidence label
- Randomized evidence
- Body topics
- Hormones
Status as of
Reference fields
Read the fields together.
- Mechanism
- Stimulates growth-hormone release.
- Evidence
- A randomized trial measured visceral fat.
- Limitations
- Not for weight management.
- Safety
- Active malignancy is a contraindication.
- Route and product context
- Specified subcutaneous formulation.
- Approval scope
- Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
A little room to think
One clearer reading question.
A shared label is a starting point for comparison, not proof that two descriptions refer to the same thing. Read the definition behind each label. Ask what would qualify for inclusion and what would be left outside. If the definitions differ, agreement in wording could hide a difference in meaning. If they match, the comparison has a firmer starting point. Make a short definition in your own words before combining the descriptions. That step helps you decide whether a difference concerns the subject itself or the way it was named.
Questions to keep nearby
- Do both uses of this label include and exclude the same things?
- Which part of each definition would decide whether an example belongs?
- Is the apparent disagreement about the subject or about how its label is defined?
Follow the record
Source list
- EGRIFTA WR
NLM · Checked
- Falutz trial
PubMed · Checked